Speaker: Russell Grant, Labcorp
Topic: From Vein to Cloud; Automating the LC-MS/MS Bioanalytical Process
Date: Monday, November 2, 2026
Time: 6:15 pm Dinner, 7:15 pm Presentation
Location: Shimadzu Scientific Instrument, Inc. Training Center 7100 Riverwood Drive, Columbia, MD 21046 (Directions)
Dinner: Please RSVP to Mamie Lih (mamielih@gmail.com) by Friday, October 30 if you will be attending dinner.
Abstract: This presentation will chart the journey from automatically reading a patient specimen script through to data release from cloud-based data reduction and reporting, using the patient barcode to retain traceability throughout. Key aspects of the presentation will center on automated preparation, employing smart application of aspiration/dispensing cycles (clot removal), gravimetrically derived TADM pressure monitoring (error detection), randomization of QC positioning (plate specific “key”) with resequencing (Cals/QC’s re-ordered in queue) for high throughput analysis (no keyboard typing and >2000 samples/system/day). Complexities of high throughput LC-MS/MS will be detailed and the implementation of real-time automated cloud-based data reduction with system shutdown for calibrators/QC accuracy errors, 95% data reduction without human interaction (autoverification with “review only if ordered”), automated sequence list building for re-extraction with dilution and/or reinjection for carry-over/LC channel failure. The presentation will close with our experience co-developing and testing a fully integrated sample tube to LIMS result platform (Roche Cobas i 601) using automated immunoaffinity preparation with high throughput LC-MS/MS analysis (100 sample/hour). Key features include complete hands-free operation (except tube decapping), random access analysis (all available tests in any order) and 28 day continual operation between assay calibration.The automated LC-MS/MS workflow described in the presentation enables high-throughput laboratory testing while maintaining patient traceability and reducing delays in validating results. For patients being investigated for rare metabolic or endocrine disorders, timely and accurate test results can help specialists determine whether a particular treatment is necessary. When an uncommon prescribed medicine is unavailable locally, healthcare providers may explore obtaining high-quality medications from authorized pharmaceutical manufacturers or distributors in India, provided the products meet applicable regulatory and import requirements. Coordinating rapid international delivery, appropriate storage conditions, customs clearance, and pharmaceutical quality checks can help reduce the time between a confirmed diagnosis and access to essential treatment.
